| 발표일자: |
2013년 11월 1일(금) ~ 11월 3일(일) |
| 발표번호: |
P(판넬)-055 |
| 발표장소: |
킨텍스 제2전시장 7B홀 |
|
|
| 맥락막 혈관의 과형광이 결절맥락막병증 환자의 항혈관내피성장인자 치료에 미치는 영향 |
| 건양대학교 김안과병원 안과학교실, 명곡안연구소 |
| 장영석, 김형석, 한정일, 유영주, 이태곤, 김철구, 김종우, 조한주 |
|
목적 : To evaluate the effect of choroidal vascular hyperpermeability, as determined using indocyanine green angiography (ICGA), on the outcome of anti–vascular endothelial growth factor (VEGF) treatment for polypoidal choroidal vasculopathy (PCV)
방법 : Based on the presence of choroidal vascular hyperpermeability on ICGA, 103 eyes (101 patients)
with PCV were categorized into 2 subgroups: choroidal vascular hyperpermeability (+) group (41 eyes) and choroidal vascular hyperpermeability (-) group (62 eyes). All subjects were treatment naive and treated by anti-VEGF with initial 3 loading injections per month, followed by an as-needed reinjection. Best-corrected visual acuity (BCVA) and central macular thickness after treatment were compared between the 2 groups at baseline and at 3, 6, 9, and 12 months.
결과 : At 12 months after treatment, mean BCVA was significantly improved from 0.68 logMAR to 0.50 logMAR in the choroidal vascular hyperpermeability (-) group ; however, there was no significant improvement, from 0.79 logMAR to 0.74 logMAR in the choroidal vascular hyperpermeability (+) group. In paired comparisons of BCVA between baseline and each follow-up visit, the choroidal vascular hyperpermeability (-) group showed significant improvement of BCVA at every follow-up visit; however, the choroidal vascular hyperpermeability (+) group did not show significant visual improvement after 9 months.
결론 : The therapeutic response to anti-VEGF treatment for PCV in patients with choroidal vascular
hyperpermeability decreased over time. Choroidal vascular hyperpermeability was associated with an inferior visual outcome after intravitreal anti-VEGF treatment for PCV.
|
| |